BACKGROUND: Axillary lymph node dissection is an established procedure in breast cancer staging. However, it is associated with unpleasant side effects. A promising alternative to assess axillary lymph node status in early breast cancer patients is Sentinel Lymph Node Biopsy (SLNB). Isosulfan blue has traditionally been the dye used to identify the Sentinel Lymph Node (SLN). This article is a validation study of SLNB using methylene blue dye and radioactive sulphur colloid in early breast cancer Indian patients. MATERIALS #ENTITYSTARTX00026; METHODS: With written informed consent, 100 patients with cytology or biospy proven carcinoma breast, clinical stage T1/ T2 N0 M0, underwent SLNB using combination of methylene blue dye & radioactive technetium 99m sulphur colloid as a part of validation study from June 2003 to February 2006. After validation study, from March 2006 to February 2007, 35 patients have undergone SLNB followed by complete axillary clearance in only those patients with SLNB being positive for metastases. RESULTS: In all 100 patients of the validation study SLN was identified. Total number of cases with positive axillary nodes was 27, out of which SLN was only positive node for metastases in 69% of cases. The overall sensitivity, specificity, positive predictive valve and negative predictive valve of SLNB 96.2%, 100%, 100% and 98.6% respectively with false negative rate of 3.7%. In subsequent 35 patients who underwent SLNB followed by complete axillary clearance, SLNs was identified in all the cases. CONCLUSIONS: SLNB is effective in early breast cancer patients of Indian population. SLNB using combination of methylene blue dye and radio-active Tc99m sulphur colloid can stage the axilla with high accuracy & low risk of false negativity in early breast cancer patients.
BACKGROUND: Axillary lymph node dissection is an established procedure in breast cancer staging. However, it is associated with unpleasant side effects. A promising alternative to assess axillary lymph node status in early breast cancerpatients is Sentinel Lymph Node Biopsy (SLNB). Isosulfan blue has traditionally been the dye used to identify the Sentinel Lymph Node (SLN). This article is a validation study of SLNB using methylene blue dye and radioactive sulphur colloid in early breast cancer Indian patients. MATERIALS #ENTITYSTARTX00026; METHODS: With written informed consent, 100 patients with cytology or biospy proven carcinoma breast, clinical stage T1/ T2 N0 M0, underwent SLNB using combination of methylene blue dye & radioactive technetium 99m sulphur colloid as a part of validation study from June 2003 to February 2006. After validation study, from March 2006 to February 2007, 35 patients have undergone SLNB followed by complete axillary clearance in only those patients with SLNB being positive for metastases. RESULTS: In all 100 patients of the validation study SLN was identified. Total number of cases with positive axillary nodes was 27, out of which SLN was only positive node for metastases in 69% of cases. The overall sensitivity, specificity, positive predictive valve and negative predictive valve of SLNB 96.2%, 100%, 100% and 98.6% respectively with false negative rate of 3.7%. In subsequent 35 patients who underwent SLNB followed by complete axillary clearance, SLNs was identified in all the cases. CONCLUSIONS: SLNB is effective in early breast cancerpatients of Indian population. SLNB using combination of methylene blue dye and radio-active Tc99m sulphur colloid can stage the axilla with high accuracy & low risk of false negativity in early breast cancerpatients.
Entities:
Keywords:
Early breast cancer; Indian patients; Methylene blue dye; Sentinel lymph node biopsy; Tc99m radioactive sulfur colloid
Authors: C E Cox; S Pendas; J M Cox; E Joseph; A R Shons; T Yeatman; N N Ku; G H Lyman; C Berman; F Haddad; D S Reintgen Journal: Ann Surg Date: 1998-05 Impact factor: 12.969
Authors: R Offodile; C Hoh; S H Barsky; S D Nelson; R Elashoff; F R Eilber; J S Economou; M Nguyen Journal: Cancer Date: 1998-05-01 Impact factor: 6.860
Authors: B J O'Hea; A D Hill; A M El-Shirbiny; S D Yeh; P P Rosen; D G Coit; P I Borgen; H S Cody Journal: J Am Coll Surg Date: 1998-04 Impact factor: 6.113
Authors: J J Albertini; G H Lyman; C Cox; T Yeatman; L Balducci; N Ku; S Shivers; C Berman; K Wells; D Rapaport; A Shons; J Horton; H Greenberg; S Nicosia; R Clark; A Cantor; D S Reintgen Journal: JAMA Date: 1996-12-11 Impact factor: 56.272
Authors: D Krag; D Weaver; T Ashikaga; F Moffat; V S Klimberg; C Shriver; S Feldman; R Kusminsky; M Gadd; J Kuhn; S Harlow; P Beitsch Journal: N Engl J Med Date: 1998-10-01 Impact factor: 91.245
Authors: S P Somashekhar; Zahoor Ahmed Naikoo; Shabber S Zaveri; Soumya Holla; Suresh Chandra; Suniti Mishra; R V Parameswaran Journal: Indian J Surg Date: 2013-02-05 Impact factor: 0.656
Authors: Sreekar Devarakonda; Shawn Sam Thomas; Supriya Sen; Varghese Thomas; Reka Karuppusami; Anish Jacob Cherian; Pooja Ramakant; Deepak Thomas Abraham; Paul Mazhuvanchary Jacob Journal: Indian J Surg Oncol Date: 2021-01-16
Authors: Jeremy Smedley; Baris Turkbey; Marcelino L Bernardo; Gregory Q Del Prete; Jacob D Estes; Gary L Griffiths; Hisataka Kobayashi; Peter L Choyke; Jeffrey D Lifson; Brandon F Keele Journal: PLoS One Date: 2014-03-25 Impact factor: 3.240